- Home
- WNW vs CUE Comparison
WNW vs CUE Comparison
Compare WNW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United States |
| Employees | N/A | 41 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 27.8M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WNW | CUE |
|---|---|---|
| Price | $1.82 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 13.4K | ★ 442.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.10 | $0.23 |
| 52 Week High | $2.95 | $1.05 |
Technical Indicators
Market Signals| Indicator | WNW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 39.65 |
| Support Level | $1.63 | $0.27 |
| Resistance Level | $1.89 | $0.36 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 88.24 | 14.60 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.